Core Viewpoint - MUSE Microscopy, Inc. has launched MUSE Veterinary Digital Pathology, LLC, a subsidiary aimed at providing same-day results for tissue biopsies in veterinary practices, enhancing diagnostic speed and precision in animal healthcare [1][2][3]. Company Overview - MUSE Microscopy specializes in digital pathology innovations, particularly through its SmartPath MUSE Technology™, which offers a slide-free direct-to-digital imaging platform for rapid diagnostic assistance [5]. Industry Impact - The formation of MUSE Veterinary Digital Pathology marks a strategic entry into the veterinary health market, focusing on point-of-care and real-time diagnostic imaging for specialty, emergency, and family veterinary practices across the U.S. [2][3]. - The initiative is expected to significantly improve clinical outcomes by reducing the wait time for biopsy results from 3-7 days to same-day diagnoses, thereby alleviating owner anxiety and enhancing medical management [4]. Leadership and Expertise - Matthew Nunez, CEO of MUSE Microscopy, will lead the new subsidiary, supported by Darin Nelson as President, who has extensive experience in scaling veterinary diagnostic companies [2][3]. - Dr. Jeffrey Edwards has been appointed as Chief Medical Officer, overseeing the anatomic pathology team and the adoption of innovative technology in veterinary practices [2]. Technological Advancements - The SmartPath platform enables rapid, non-destructive tissue imaging, allowing veterinarians to make real-time treatment decisions and perform intraoperative assessments without relying on conventional slide-based workflows [2][3][4]. - The technology aims to empower veterinarians with powerful diagnostic tools directly at the point-of-care, facilitating faster decision-making and improved patient care [4]. Future Developments - MUSE Veterinary Digital Pathology will operate independently while leveraging MUSE Microscopy's existing infrastructure and anticipates further announcements regarding pilot partnerships and distribution opportunities in the coming months [4].

TransMedics Group (TMDX) FY Conference June 09, 2025 08:00 AM ET Speaker0 morning, and welcome to the twenty twenty five Goldman Sachs Global Healthcare Conference. My name is Phil Cooper. I'm part of David Roman's U. S. Med tech and health care IT team. We're pleased to be joined by TransMedics this morning. We have the founder, president, and CEO, Waleed Hassanein, and CFO, Gerardo Hernandez. Before we begin, I have some disclosures that I'm gonna try and read really quickly. We are required to make certa ...

Core Insights - The 2025 Veeva MedTech Postmarket Quality Benchmark Report indicates that 88% of surveyed medtech companies are advancing postmarket quality management within the next three years to enhance compliance and innovation [1][7] - A significant portion of medtech companies, 68%, still rely on manual processes, which can lead to delays in addressing product issues and backlogs in complaint handling [2][7] - The report highlights the need for proactive and risk-based quality management, with 38% of respondents identifying it as a primary driver for advancing quality [3] Industry Trends - There is a strong emphasis on technology as an enabler for quality management, with 75% of respondents believing that advanced technology can drive automation for faster timelines and efficiency [4] - Despite the potential benefits, generative AI and robotic process automation are scarcely adopted, with less than 3% of companies applying these technologies reliably [5] - Gaps in employee training are evident, as only 19% of respondents feel their training programs adequately support postmarket quality teams [6] Strategic Recommendations - Organizations are encouraged to align strategic goals with modern technology solutions to transition from reactive issue management to proactive risk prevention [7] - The report suggests that streamlining quality operations can lead to improved management and execution, particularly through proactive actions and scaling processes [3][4]

Group 1 - Sanara MedTech (SMTI) shares have faced pressure this year despite strong growth and improving profitability in the Surgical segment, primarily due to concerns over rising debt levels [1] - The company operates in a sector that is often under-researched, focusing on small to mid-cap companies with potential asymmetric investment opportunities [1] Group 2 - The article reflects the author's personal investment experience and analysis, emphasizing the importance of thorough research in identifying market-beating returns [1]

Core Points - TELA Bio, Inc. announced the approval of an inducement grant of stock options and restricted stock units to Jim Hagen, the Senior Vice President of Strategic Commercial Operations, as part of his employment compensation [1][2] - The stock options have an exercise price of $1.42 per share, with a ten-year term and a vesting schedule over four years [2] - TELA Bio focuses on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's own anatomy [3] Summary by Category Inducement Grant Details - The Compensation Committee approved an option to purchase 75,000 shares and restricted stock units covering 30,000 shares for Jim Hagen [1] - The stock options will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal monthly installments over the following 36 months [2] - The restricted stock units will vest in equal annual installments over four years [2] Company Overview - TELA Bio is a commercial-stage medical technology company [3] - The company aims to provide advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response [3] - TELA Bio minimizes long-term exposure to permanent synthetic materials in its solutions [3]

New York, NY , June 06, 2025 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that on June 5, 2025, it caused to be deposited $0.15 per public share, totaling $10,890.15 (the “Extension Payment”) into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”) to extend the deadline to complete its initial business combination from June 9, 20 ...

Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and mark ...

MADISON, Wis., June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares" ...

Group 1: Breakthrough in Visual Prosthetics - Chinese scientists have developed the world's first visual prosthetic with ultra-wide spectral response capabilities, enabling blind animals to regain visible light vision and expand their visual functions [1] - The retinal prosthetic, based on tellurium nanowire networks (TeNWNs), covers a spectral range from visible light (470nm) to near-infrared (1550nm), surpassing the natural human vision range of 380-780nm [1] - This technology avoids the risks associated with invasive brain surgeries and breaks the physiological limits of human vision, allowing users to perceive infrared light and accurately locate infrared light sources [1] Group 2: Growth of Brain-Computer Interface (BCI) Market - The global brain-computer interface technology is rapidly advancing, with significant attention from tech companies, medical institutions, academic research organizations, and government departments [2] - McKinsey predicts that the BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040, with serious medical applications for central nervous system diseases estimated at $15 billion in 2030 and $85 billion in 2040 [2] - The domestic BCI companies are expected to gradually achieve commercialization due to technological innovations and favorable policies promoting industry development [2] Group 3: Related Companies in the BCI Sector - Micron Brain Science (02172) is a leading company in the domestic neuro-interventional medical device field, covering hemorrhagic stroke, atherosclerosis, and acute ischemic stroke, maintaining the top position in the domestic market share [3] - Xinwei Medical-B (06609) successfully completed animal trials for China's first interventional brain-computer interface, developed in collaboration with Nankai University's AI team [3] - Nanjing Panda Electronics (00553) is involved in the development of a multimodal human-computer interaction system based on BCI technology, which has been included in Jiangsu Province's key research and development plan [3]

2 June 2025 | 2:08AM PDT Americas Healthcare: MedTech & HCIT: Leaning Into Growth and Reinvestment Thesis Heading to the halfway point of 2025 and the Goldman Sachs 46th Annual Healthcare Conference, we review takeaways from YTD results, market due diligence, and management meetings that set the foundation for the balance of the year. The following summarizes key takeaways from a fundamental perspective: David Roman +1(212)357-4617 | david.roman@gs.com Goldman Sachs & Co. LLC Jamie Perse, CFA +1(212)902-819 ...